Clinical trial NCT01261754: A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
Official title: A Phase I Study of the PK, Tissue Distribution and Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen, 99mTc-MIP-1404 and 99mTc-MIP-1405, in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Prostate Cancer
Keywords: Metastatic Prostate Adenocarcinoma
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2010-12-16
Enrollment: 16
Sex: MALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This is a single-blind, randomized, cross-over design. Patients with metastatic prostate adenocarcinoma; newly diagnosed, high-risk patients with prostate adenocarcinoma; and healthy subjects will be administered a single intravenous dose of each of the study drugs 99mTc MIP 1404 and 99mTc MIP 1405 administered approximately 14 to 21 days apart.

Detailed description: This trial is a single-blind, randomized, cross-over design. Up to six patients with confirmed metastatic prostate adenocarcinoma; six newly diagnosed, high-risk patients with prostate adenocarcinoma; and up to six healthy volunteers will receive 20.0 (± 3) mCi of intravenously administered 99mTc MIP 1404 or 99mTc MIP 1405. Whole-body planar scintigraphic images will be acquired at various times post-injection over 24 hours. A pelvic SPECT/CT image will be acquired on the first day. Blood and urine will be collected for pharmacokinetic measurements and metabolic analysis over 24 hours. Each patient will receive an initial study drug administration and a second study drug administration approximately 14 to 21 days after the first. A final follow-up visit will occur approximately 2-3 weeks after the second study drug.

Eligibility criteria: Inclusion Criteria:

Participants must meet all of the following criteria to be enrolled in this study.

1. Male aged 21 years or older.
2. Ability to provide signed informed consent and willingness to comply with protocol requirements.
3. Participants must agree to use condoms for a period of seven days after each injection, if engaged in sexual activity.

Additional Inclusion Criteria for Patients:

i. Histologic diagnosis of prostate cancer by validated medical history. (Pathology report, if available).

ii. Evidence of metastatic disease demonstrated by a documented abnormal bone scan, CT scan, or MRI plus a Clinical Stage 3 and Gleason Score ≥ 8.

iii. Karnofsky performance is ≥ 60.

Additional Inclusion Criteria for Healthy Volunteers:

i. PSA laboratory assessment within normal range (PSA \< 4 ng/ml). ii. Normal findings on a digital rectal examination. iii. Hemoglobin and hematocrit within normal range.

Exclusion Criteria:

Participants must NOT meet any of the following criteria to be enrolled in this study.

1. Received an investigational compound and/or medical device or is part of an investigational study within the past 30 days before enrollment into this study.
2. Subject was administered a radioisotope within 5 physical half lives of that radioisotope prior to study enrollment
3. Have any medical condition or other circumstances which, in the opinion of the Investigator, would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations.
4. Participant is determined by the Investigator to be clinically unsuitable for the study.
5. Serum creatinine ≥ 2.0 mg/dl
6. Total bilirubin ≥ 2.0 mg/dl
7. Liver transaminases ≥ 1.5 x ULN
8. Platelet count \< 150,000/mm3
9. Absolute neutrophil count (ANC) \< 2,000/mm3.
10. Hematocrit \< 30% or hemoglobin \< 10 g/dl.
11. Abnormal coagulation profile (PT, PTT or INR) \> 1.3 ULN unless on therapeutic anticoagulation.

Additional Exclusion Criteria for Patients:

Patients will be excluded from the study if any of the following criteria are observed:

i. Androgen deprivation therapy or other forms of hormonal therapy not stable for a period of 14 days prior to screening.

ii. Subject has received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants; or 12 months for 125I implants.

iii. Subject on or expected to be starting cytotoxic chemotherapy during the study period.

iv. Has had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, diagnosis and location must be defined or be defined as clinically controlled or treated to complete response.

Additional Exclusion Criteria for Healthy Volunteers:

Healthy Volunteers will be excluded from the study if any of the following criteria are observed:

i. Have had any malignancies within 5 years other than basal or squamous cell carcinoma of the skin.

ii. History of known prostate adenocarcinoma, prostate surgery/biopsy, prostatitis and/or symptoms suggestive of or associated with possible prostatitis within 6 months of enrollment.

Primary outcomes:
measure: Safety of Administered dose
timeFrame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
measure: Pharmacokinetics of Administered Dose
timeFrame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
measure: Biodistribution of Administered Dose
timeFrame: : From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
Secondary outcomes:
measure: Excretion of administered dose
timeFrame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
measure: Dosimetry of administered dose
timeFrame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
measure: Metabolism of administered dose
timeFrame: From the time of signed ICF through 2 weeks post injection of the second study drug administration (up to 8 weeks total for each subject)
Other outcomes:
Locations:
city: New York
country: United States
facility: New York Presbyterian Hospital - Weill Medical College of Cornell University
state: New York
Study officials:
affiliation: New York Presbyterian Hospital - Weill Medical College of Cornell University
name: Stanley J Goldsmith, MD
role: PRINCIPAL_INVESTIGATOR
References: